Small Cap Feast

Small Cap Feast – 31 March 2020

Dish of the Day:

No Joiners Today


Off the Menu:

No Leavers Today


What’s Cooking in the IPO Kitchen?

Main Market (Premium)

DRI Healthcare—investment company focused on investments in healthcare Royalty Assets  looking to raise $350m.  Timetable now extended.


Breakfast Buffet

Leeds Group 9.5p £2.6m (LDSG.L)

 COVID-19 trading update.

Leeds Group’s activities in Germany, Hemmers/Itex Textil Import Export GmbH  and Stoff-Ideen-KMR GmbH  have been severely affected by the country wide lockdown imposed by the German government.

The wholesale business of Hemmers has been considerably restricted and all retail shops in KMR have been closed until further notice.  As a result, the trading results for the 3-month period from March to May 2020 will be affected.

Whilst the directors are taking mitigating actions which includes support from government schemes, the benefit in the current financial year will be limited given the proximity to the May year end. Therefore, in addition to the reduced trading announced in the Interim Statement issued on 3 February 2020, the Board expects to report a substantial loss for the financial year to 31 May 2020.


TMT Investments* $1.85 $56m (TMT.L)

In respect of COVID-19, TMT confirms:

  • No disruption to the Company’s activities;
  • Strong balance sheet with cash reserves of approximately US$10.7 million and no financial debt;
  • Increased engagement with the Company’s portfolio companies to assess impact of COVID-19 and providing advice and support where needed;
  • Majority of TMT’s portfolio companies are well positioned to weather the impact of COVID-19; and
  • ·   Selective investment approach given COVID-19, will likely mean no significant new investments in the coming months.


Kape Technologies 178p £288m (KAPE.L)

The digital security and privacy software business, provides an update regarding the impact of COVID-19.

As a result of the restrictions being imposed on movement across the globe in response to the COVID-19 pandemic, and an increase in both remote and home working, Kape has seen increased demand for its products. This has been especially apparent within the Group’s digital privacy division, and in particular Kape’s VPN offering has experienced increased demand globally but most notably from North America and Europe.

Demand for Kape’s digital privacy products is robust, and the Group is on track to deliver revenues of $120-123 million and Adjusted EBITDA of $35-38 million in 2020.


Quixant 55.5p £36.9m (QXT.L)

Update from the leading provider of innovative, highly engineered technology products principally for the global gaming and broadcast industries.

  • Group has seen a robust performance in first quarter 2020 trading despite supply chain challenges
  • However the shutdown of the gaming sector and many other industries for an indefinite period clearly presents a material uncertainty to the Group’s operations
  • Withdrawing guidance for 2020 and thereafter
  • Cash conservation, employee safety and protection of the business to support normal operations once we see demand returning is our immediate priority.
  • Net cash of $17.7m at 29 February 2020 (gross cash of $18.5m) with undrawn bank facilities of $3.0m

o Change in board composition – Effective 31 May 2020, Nick Jarmany will become non-executive deputy chairman, Gary Mullins will become a non-executive director and C-T Lin will step down from board responsibilities but continue to support the Taiwanese operation as a consultant.  Gaye Hudson will also leave the board effective 19 May 2020.


Harvest Minerals 3p £5.6m (HMI.L)

Corporate Update ·


o  No impact yet on Harvest’s operations, but continue to monitor closely

o  Series of measures implemented to keep staff, customers and local community safe

  • Financials

o  Debt free, positive working capital position of AUD$9.7 million as at 31 December 2019 – a strong balance sheet

o  Annual Financial Results to 31 December 2019 now expected in late Q2 2020 – delay due to the pandemic

  • Sales and Marketing

o  Sales and Marketing teams expanded to provide coverage in two new geographical areas

o  Orders up 150% to the end of February 2020 compared to the same period last year

  • Operations and Sustainability

o  Expansion of both footprint of the operating mine and product storage facility underway

o  Planting 18,000 native trees during 2020 to become a carbon free company


Sigma Capital 70p £62.7m (SGM.L)

The private rented sector, residential development and urban regeneration specialist,  announced the appointment of Michael McGill to the Board as Group Chief Financial Officer. As well as taking executive responsibility for the overall financial management of the Group and its subsidiaries, Mike will be specifically responsible for financial matters relating to The PRS REIT including leading a dedicated finance team that has been established to support the REIT’s ongoing growth. Malcolm Briselden, Finance Director of Sigma, remains in operational charge of Sigma’s finance team, working closely with Mike although he steps down from the Board today.

Mike, has over 20 years of experience in senior financial roles at listed and private companies. He was previously Group CFO at Baxters Food Group Limited, the international food processing company, CFO at Lomond Capital, the residential asset management company, and Group Finance Director at Murray International Holdings Limited, the property and metals group.


Distil 0.8p £4m (DIS.L)

Termination of its joint venture agreement with British Honey Company with immediate effect.

This agreement, made prior to the UK outbreak of Covid-19, was designed to allow our teams to jointly create a shared new product. As it was only formed in February this year, development work is at an early stage with relatively little cost incurred. Has to cancel this contract with immediate effect and both companies will extract their funds to focus on  individual opportunities and priorities.

Distil will continue to prepare exciting new brands and liquids in anticipation of the wider market reopening at a later date. These new brands will now be wholly owned by Distil. The impact of Covid-19 has led to the closure of pubs, bars and restaurants and increased demand from the retail sector, both through stores and online. Focusinr immediate efforts on working with  distributors and production partners to supply a changing demand landscape across trade channels.   Remains in line with market expectations following a strong Q4.


Falanx Group 0.95p £3.8m (FLX.L)

FY Mar 20 trading.  Update as to its expected results for the year ended 31 March 2020 and the impact of the ongoing global COVID-19 crisis. New customer wins (the majority of the revenue for which will be recognised in the next financial year), combined with much stronger recurring revenues in the Assynt strategic intelligence division, result in the Board expecting to deliver revenues of circa £5.9m for the year ended 31 March 2020 representing growth of 13% on last year. Overall, the Company currently expects to be able to operate effectively within its existing resources and will closely monitor the ongoing situation.

The Assynt division is a highly respected strategic intelligence consultancy specialising in the forecasting and interpretation of geopolitical business and security risks in emerging markets. Recent coverage has been extended to include the analysis of political, security, health and cyber-related risks from the outbreak of COVID-19 in these markets. Summaries of these reports are available at


Synairgen 68.5p £83m (SNG.L)

The respiratory drug discovery and development company, today announces that it has now commenced dosing patients in its trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients. This announcement follows the one made by the Company on 18 March 2020.

The first patient has been dosed at the initial trial site (University Hospital Southampton NHS Foundation Trust). Synairgen has initiated a further six trial sites which are expected to start dosing in the coming days.


Intercede Group 44.5p £22.5m (IGP.L)

The specialist in digital identity, credential management and secure mobility, is pleased to announce the receipt of a large US Federal Government order totaling $4.6m. The order, which was included within the directors’ expectations for the year, includes software licenses and annual support & maintenance; $2.05m of which will be recognised in the financial year ending 31 March 2020.

In line with normal practice, a Trading Update will be provided as soon as possible after the completion of the financial year.


Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.